Xencor, Inc. (NASDAQ:XNCR) Shares Sold by US Bancorp DE

US Bancorp DE trimmed its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,375 shares of the biopharmaceutical company’s stock after selling 532 shares during the period. US Bancorp DE’s holdings in Xencor were worth $209,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Texas Permanent School Fund Corp increased its holdings in Xencor by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 690 shares in the last quarter. Linden Thomas Advisory Services LLC increased its holdings in Xencor by 1.6% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock worth $826,000 after acquiring an additional 699 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 744 shares during the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Xencor by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 900 shares during the last quarter. Finally, Diversified Trust Co lifted its position in shares of Xencor by 7.8% in the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 1,017 shares in the last quarter.

Wall Street Analysts Forecast Growth

XNCR has been the subject of several research reports. JPMorgan Chase & Co. boosted their price target on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Wedbush reiterated an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Finally, Royal Bank of Canada boosted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.75.

Insider Buying and Selling

In related news, VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total value of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at approximately $4,698,441.92. The trade was a 25.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bassil I. Dahiyat sold 3,366 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total transaction of $80,851.32. Following the transaction, the chief executive officer now directly owns 352,615 shares of the company’s stock, valued at approximately $8,469,812.30. This trade represents a 0.95 % decrease in their position. The disclosure for this sale can be found here. 5.23% of the stock is currently owned by company insiders.

Xencor Stock Down 0.5 %

NASDAQ XNCR opened at $23.50 on Friday. The business’s fifty day simple moving average is $20.84 and its 200-day simple moving average is $20.37. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.64 billion, a PE ratio of -7.34 and a beta of 0.66. Xencor, Inc. has a 52 week low of $15.31 and a 52 week high of $26.84.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same period in the previous year, the firm earned ($0.40) earnings per share. Xencor’s quarterly revenue was down 81.9% compared to the same quarter last year. As a group, equities analysts anticipate that Xencor, Inc. will post -3.79 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.